Phoenix is pleased to announce its latest investment in FutureMeds, a group of research sites providing patient recruitment and clinical trial management services across Europe.
Phoenix is partnering with FutureMeds’ three co-founders; Dr Radoslaw Janiak (CEO), Marcin Gondek (CFO) and Paul Chambers (Chair). Having started the business in 2020, they have grown FutureMeds quickly to be the leading independent site management organisation (SMO) across Europe. The company provides end-to-end clinical trial services, including patient recruitment, clinical trial execution and hybrid/virtual trial services for major global pharma sponsors and Contract Research Organisations (CROs). Today, the business operates 28 clinical sites across 7 European countries with hybrid/virtual solutions in 18 different countries. Phoenix will support FutureMeds through its next stage of growth, as it continues to deliver high-quality clinical trials, contributing to the development of innovative new therapies.
Phoenix’s investment strategy focuses on founder-led businesses in high-growth niches where it has deep expertise. This investment in FutureMeds marks the tenth from Phoenix’s current fund and builds on the firm’s strong track record in Outsourced Pharma Services, exemplified by its former successful partnership with Sygnature Discovery, a leading provider of integrated drug discovery services.
Phoenix’s partnership with FutureMeds will help the company expand its geographic footprint, increase patient recruitment, deliver a greater volume of trials, and deepen its expertise across a broader range of therapeutic areas. FutureMeds is already Europe’s largest independent SMO network, and with Phoenix as its partner, it is well-positioned to accelerate its growth.
Phoenix has built a strong relationship with the FutureMeds team over several years, and the investment reflects both confidence in the management team and conviction in the opportunity ahead.
Dr Radoslaw Janiek, Co-Founder & CEO, FutureMeds, commented:
“Our success to date has been driven by the exceptional people across FutureMeds who bring deep commitment, clinical expertise and a shared culture focused on excellence. We are proud of what we have built together and believe Phoenix is the right partner to support us in the next phase of our journey.”
Paul Chambers, Co-Founder & Chair, FutureMeds, commented:
“We have grown FutureMeds into the largest SMO network in Europe, but we are still just scratching the surface of what is possible. The opportunity ahead to expand our reach, broaden our capabilities and serve even more patients and sponsors is enormous. We see our partnership with Phoenix as an important step in unlocking the next phase of scale and ambition.”
Kevin Keck, Managing Partner at Phoenix, commented:
“We have known Radek, Marcin and Paul for several years and have been consistently impressed by the vision, dedication and quality of the team they have built”
Barry Robinson, Partner at Phoenix, added:
“Our investment reflects Phoenix’s continued commitment to partnering with founder-led businesses in sectors where we have deep research and conviction. We’re really looking forward to the journey ahead.”
